[1]邵景萍.米非司酮周期疗法与孕激素治疗围绝经期异常子宫出血的临床效果[J].医学信息,2022,35(08):153-155.[doi:10.3969/j.issn.1006-1959.2022.08.039]
　SHAO Jing-ping.The Clinical Effect of Mifepristone Cycle Therapy and Progesterone in the Treatment of Perimenopausal Abnormal Uterine Bleeding[J].Medical Information,2022,35(08):153-155.[doi:10.3969/j.issn.1006-1959.2022.08.039]
点击复制

米非司酮周期疗法与孕激素治疗围绝经期异常子宫出血的临床效果()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年08期
页码:
153-155
栏目:
药物与临床
出版日期:
2022-04-15

文章信息/Info

Title:
The Clinical Effect of Mifepristone Cycle Therapy and Progesterone in the Treatment of Perimenopausal Abnormal Uterine Bleeding
文章编号:
1006-1959（2022）08-0153-03
作者:
邵景萍
（1.天津医科大学总医院滨海医院神经内科，天津 300480；2.河北北方学院附属第二医院心内科，河北 张家口 075100）
Author(s):
SHAO Jing-ping
(Department of Gynecology,Tianjin Jizhou District People’s Hospital,Tianjin 301900,China)
关键词:
匹伐他汀; 阿托伐他汀; 缺血性卒中; 血脂; NIHSS评分
Keywords:
ifepristone cycle therapy; Progesterone; Perimenopausal period; Abnormal uterine bleeding
分类号:
R543
DOI:
10.3969/j.issn.1006-1959.2022.08.039
文献标志码:
A
摘要:
目的 比较匹伐他汀与阿托伐他汀治疗缺血性卒中患者的疗效及安全性。方法 选取2017年10月-2018年9月天津医科大学总医院滨海医院接诊的100例缺血性卒中患者为研究对象，采用随机数字表法分为对照组和观察组，各50例。对照组采用阿托伐他汀治疗，观察组采用匹伐他汀治疗，比较两组临床治疗总有效率、血脂指标、NIHSS评分、血肌酐、尿素氮、白细胞计数、血小板计数、尿蛋白阳性率。结果 观察组治疗总有效率为86.00%，高于对照组的82.00%，差异无统计学意义（P＞0.05）；两组LDL-C、TG、TC均低于治疗前，且观察组低于对照组，差异有统计学意义（P＜0.05）；两组NIHSS评分均低于治疗前，差异有统计学意义（P＜0.05），但组间比较，差异无统计学意义（P＞0.05）；观察组血肌酐、尿素氮、白细胞计数、尿蛋白阳性率均低于对照组，血小板计数高于对照组，差异有统计学意义（P＜0.05）。结论 匹伐他汀与阿托伐他汀对缺血性卒中疗效相似，但匹伐他汀降低血脂水平更显著，且可一定程度缓解药物不良反应，具有一定的临床应用优势。
Abstract:
Objective To observe the clinical effect of mifepristone cycle therapy and progesterone in the treatment of perimenopausal abnormal uterine bleeding.Methods A total of 72 patients with perimenopausal abnormal uterine bleeding treated in our hospital from June 2020 to June 2021 were selected as the research subjects. They were divided into control group and observation group by random number table method, with 36 cases in each group. The control group was treated with progesterone, and the observation group was treated with mifepristone cycle therapy. The clinical efficacy, endometrial thickness, menstrual cycle, bleeding control time, sex hormone levels and adverse reactions were compared between the two groups.Results The total effective rate of the observation group was 88.89%, which was higher than 77.78% of the control group, and the difference was statistically significant (P<0.05). The endometrial thickness of the two groups was lower than that before treatment, and the observation group was lower than the control group, the difference was statistically significant (P<0.05). The bleeding control time and menstrual cycle of the observation group were shorter than those of the control group, and the difference was statistically significant (P<0.05). The levels of estradiol in the observation group were lower than those in the control group, and the levels of follicle estrogen and luteinizing hormone in the observation group were higher than those in the control group, the difference was statistically significant (P<0.05). The incidence of adverse reactions in the observation group was 5.56%, which was lower than 13.89% in the control group, and the difference was statistically significant (P<0.05).Conclusion The total effective rate of mifepristone cycle therapy in the treatment of perimenopausal abnormal uterine bleeding is high, which can quickly control abnormal bleeding, shorten menstrual cycle, improve sex hormone levels, have fewer adverse reactions and good safety.

参考文献/References:

[1]申铁英．小剂量米非司酮联合补肾固冲汤治疗围绝经期功能失调性子宫出血的临床效果[J].世界中西医结合杂志,2017,12(4):538－540．[2]辛路平,蒋清清．不同方案治疗围绝经期功血的效果与安全性[J].中国性科学,2019,28(7):106-109．[3]张世应,孙绪举.围绝经期功能性子宫出血采用去氧孕烯炔雌醇(妈富隆)联合小剂量米非司酮治疗的临床疗效观察[J].中国妇幼保健,2020,35(9):1686-1689.[4]周维.不同剂量米非司酮对围绝经期功能失调性子宫出血的疗效[J].实用药物与临床,2018,21(1):64-66．[5]高梅.分析围绝经期异常子宫出血患者采用曼月乐联合米非司酮治疗的临床效果[J].世界中医药,2017,26(1):401.[6]张守娥,张琼阁,卢保华.诊刮术联合小剂量米非司酮治疗围绝经期功能失调性子宫出血疗效观察[J].人民军医,2017,8(10):989-991.[7]赵玉玲,王海艳,阎凌,等.米非司酮2种用药方案治疗围绝经期功能障碍性子宫出血临床疗效对比[J].西北国防医学杂志,2016,37(5):291-294.[8]郁琦围绝经期异常子宫出血诊断和治疗专家共识[J].协和医学杂志,2018,9(4):313-319．[9]王婷婷.小剂量米非司酮联合戊酸雌二醇治疗围绝经期功能失调性子宫出血的疗效观察[J].中国医院用药评价与分析,2016,16(7):915-917. [10]李海英,邱建敏,高翔.小剂量米非司酮2 次疗法对月经周期的调节作用[J].中国妇幼保健,2017,32(11):2423-2425.[11]曲波,刘红,杜盟盟,等.曼月乐和安宫黄体酮在围绝经期异常子宫出血治疗中的疗效分析[J].生殖与避孕,2016,36(1):65-68．[12]买卫红.左炔诺孕酮宫内节育系统联合子宫内膜电切术治疗围绝经期异常子宫出血的效果[J].河南医学研究,2020,29(9):1602-1603.[13]何晓丽.左炔诺孕酮宫内缓释系统治疗功能失调性子宫出血的临床效果[J].医学综述,2016,22(15):3099-3101.[14]闫丽华.地屈孕酮在排卵障碍性异常子宫出血中的应用探讨[J].吉林医学,2019,40(4):774-775.[15]梁红艳.卡前列素氨丁三醇应用于高危妊娠产后出血的临床效果研究[J].河北医学,2020,26(5):744-747.[16]张碧黎,王依静,张雪芹.去氧孕烯炔雌醇片治疗围绝经期功能失调性子宫出血的临床研究[J].中国临床药理学杂志,2017,33(7):599-601.[17]蓝美萍,邹燕珠.中药周期疗法联合热敏灸治疗青春期功能失调性子宫出血43例[J].河南中医,2017,37(2):310-312.[18]陈艳琴,黄凌云,顾燕芳,等.达英-35、炔诺酮和黄体酮治疗围绝经期异常子宫出血疗效及安全性分析[J].北华大学学报（自然科学版）,2019,20(4):502-505.[19]蒙俊,韦静,兰晏逢,等.诺舒阻抗控制子宫内膜切除系统与左炔诺孕酮宫内缓释系统治疗功能失调性子宫出血的疗效对比[J].广西医学,2016,38(7):979-982. [20]王敏华,陈丽萍,吕美雅.米非司酮联合左炔诺孕酮宫内节育系统治疗围绝经期功能失调性子宫出血的疗效和安全性[J].中国新药与临床杂志,2018,37(7):409-412.

相似文献/References:

[1]何 丽.三种他汀类药物治疗老年动脉粥样硬化性急性脑梗死合并高血脂效果对比[J].医学信息,2022,35(11):150.[doi:10.3969/j.issn.1006-1959.2022.11.040]
　HE Li.Comparison of Three Statins in the Treatment of Elderly Patients with Atherosclerotic Acute Cerebral Infarction Combined with Hyperlipidemia[J].Medical Information,2022,35(08):150.[doi:10.3969/j.issn.1006-1959.2022.11.040]
[2]王 毅.阿托伐他汀联合曲美他嗪治疗冠心病的临床效果评价[J].医学信息,2018,31(13):139.[doi:10.3969/j.issn.1006-1959.2018.13.041]
　WANG Yi.Clinical Evaluation of Atto Vastatin Combined with Trimetazidine in the Treatment of Coronary Atherosclerotic Heart Disease[J].Medical Information,2018,31(08):139.[doi:10.3969/j.issn.1006-1959.2018.13.041]
[3]王润俊.阿托伐他汀改善蛛网膜下腔出血患者的预后分析[J].医学信息,2018,31(14):142.[doi:10.3969/j.issn.1006-1959.2018.14.043]
　WANG Run-jun.Analysis of Atorvastatin Improves Prognosis in Patients with Subarachnoid Hemorrhage[J].Medical Information,2018,31(08):142.[doi:10.3969/j.issn.1006-1959.2018.14.043]
[4]袁 敏,周袁成.阿托伐他汀联合抗血小板药治疗脑血栓患者的疗效及对 血小板参数的影响[J].医学信息,2018,31(16):123.[doi:10.3969/j.issn.1006-1959.2018.16.038]
　YUAN Min,ZHOU Yuan-cheng.Effect of Atorvastatin Combined with Antiplatelet Drugs on Patients with Cerebral Thrombosis and its Influence on Platelet Parameters[J].Medical Information,2018,31(08):123.[doi:10.3969/j.issn.1006-1959.2018.16.038]
[5]徐润鸿.血府逐瘀汤联合阿托伐他汀钙治疗急性脑梗死的临床观察[J].医学信息,2019,32(05):165.[doi:10.3969/j.issn.1006-1959.2019.05.054]
　XU Run-hong.Clinical Observation on Treatment of Acute Cerebral Infarction with Xuefu Zhuyu Decoction Combined with Atorvastatin Calcium[J].Medical Information,2019,32(08):165.[doi:10.3969/j.issn.1006-1959.2019.05.054]
[6]沈有录,卢红涛,刘维军.阿托伐他汀和瑞舒伐他汀对高海拔地区PCI患者血脂、炎症因子和血管内皮功能的影响[J].医学信息,2019,32(06):67.[doi:10.3969/j.issn.1006-1959.2019.06.022]
　SHEN You-lu,LU Hong-tao,LIU Wei-jun.Effects of Atorvastatin and Rosuvastatin on Blood Lipids,Inflammatory Factors and Vascular Endothelial Function in Patients with High Altitude PCI[J].Medical Information,2019,32(08):67.[doi:10.3969/j.issn.1006-1959.2019.06.022]
[7]陈志萍.阿托伐他汀联合低分子肝素治疗短暂性脑缺血临床疗效[J].医学信息,2019,32(09):153.[doi:10.3969/j.issn.1006-1959.2019.09.051]
　CHEN Zhi-ping.Clinical Efficacy of Atorvastatin Combined with Low Molecular Weight Heparin in the Treatment of Transient Cerebral Ischemia[J].Medical Information,2019,32(08):153.[doi:10.3969/j.issn.1006-1959.2019.09.051]
[8]高占群,李 霜,刘 杨.苯那普利联合阿托伐他汀治疗冠心病合并2型糖尿病 心功能不全的临床效果[J].医学信息,2019,32(17):135.[doi:10.3969/j.issn.1006-1959.2019.17.044]
　GAO Zhan-qun,LI Shuang,LIU Yang.Clinical Effect of Benazepril Combined with Atorvastatin in the Treatment of Coronary Heart Disease Complicated with Type 2 Diabetes with Cardiac Insufficiency[J].Medical Information,2019,32(08):135.[doi:10.3969/j.issn.1006-1959.2019.17.044]
[9]安志卫,刘 娜,薛芳芳.阿托伐他汀联合硫酸氢氯吡格雷治疗脑血栓的效果观察[J].医学信息,2019,32(17):148.[doi:10.3969/j.issn.1006-1959.2019.17.049]
　AN Zhi-wei,LIU Na,XUE Fang-fang.Effect of Atorvastatin Combined with Clopidogrel Hydrogen Sulfate on Cerebral Thrombosis[J].Medical Information,2019,32(08):148.[doi:10.3969/j.issn.1006-1959.2019.17.049]
[10]花国辉.不同剂量阿托伐他汀治疗心梗后无症状心衰的疗效比较[J].医学信息,2020,33(04):153.[doi:10.3969/j.issn.1006-1959.2020.04.050]
　HUA Guo-hui.Comparison of the Effects of Different Doses of Atorvastatin on Asymptomatic Heart Failure After Myocardial Infarction[J].Medical Information,2020,33(08):153.[doi:10.3969/j.issn.1006-1959.2020.04.050]

更新日期/Last Update: 1900-01-01